
## Antonino Di Caro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/491608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Easy-to-Use SARS-CoV-2 Assembler for Genome Sequencing: Development Study. JMIR Bioinformatics and Biotechnology, 2022, 3, e31536.	0.4	5
2	Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing. International Journal of Environmental Research and Public Health, 2021, 18, 2174.	1.2	59
3	16S rRNA gene sequencing of rectal swab in patients affected by COVID-19. PLoS ONE, 2021, 16, e0247041.	1.1	36
4	COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020. Biomolecules, 2021, 11, 425.	1.8	22
5	Importance of Surveillance of New Delhi Metallo-Beta-Lactamase Klebsiella pneumoniae: Molecular Characterization and Clonality of Strains Isolated in the Lazio Region, Italy. Infection and Drug Resistance, 2021, Volume 14, 3659-3665.	1.1	4
6	Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021. Frontiers in Medicine, 2021, 8, 815870.	1.2	8
7	SARS-CoV-2 Phylogenetic Analysis, Lazio Region, Italy, February–March 2020. Emerging Infectious Diseases, 2020, 26, 1842-1845.	2.0	33
8	Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect― Journal of Global Antimicrobial Resistance, 2020, 23, 290-291.	0.9	63
9	Chikungunya Outbreak in the Republic of the Congo, 2019—Epidemiological, Virological and Entomological Findings of a South-North Multidisciplinary Taskforce Investigation. Viruses, 2020, 12, 1020.	1.5	15
10	Compartmentalized Replication of SARS-Cov-2 in Upper vs. Lower Respiratory Tract Assessed by Whole Genome Quasispecies Analysis. Microorganisms, 2020, 8, 1302.	1.6	40
11	Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. Journal of Infectious Diseases, 2020, 222, 1807-1815.	1.9	167
12	Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. Open Forum Infectious Diseases, 2020, 7, ofaa403.	0.4	17
13	Active Pulmonary Tuberculosis in Elderly Patients: A 2016–2019 Retrospective Analysis from an Italian Referral Hospital. Antibiotics, 2020, 9, 489.	1.5	34
14	Lessons from the COVID-19 Pandemic—Unique Opportunities for Unifying, Revamping and Reshaping Epidemic Preparedness of Europe's Public Health Systems. International Journal of Infectious Diseases, 2020, 101, 361-366.	1.5	8
15	Reduced Susceptibility to Carbapenems in a Klebsiella pneumoniae Clinical Isolate Producing SCO-1 and CTX-M-15 β-Lactamases Together with OmpK35 and OmpK36 Porin Deficiency. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7
16	COVID-19 disease—Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. PLoS ONE, 2020, 15, e0244129.	1.1	35
17	Title is missing!. , 2020, 15, e0244129.		0

2

#	Article	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0244129.		Ο
20	Title is missing!. , 2020, 15, e0244129.		0
21	Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy. Clinical Microbiology and Infection, 2019, 25, 203-209.	2.8	43
22	<p>Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in <em>bla</em><sub>KPC-3</sub>-harboring <em>Klebsiella pneumoniae</em></p> . Infection and Drug Resistance, 2019, Volume 12, 1935-1940.	1.1	22
23	>Multidrug-Resistant Tuberculosis In A Referral Center In Rome: 2011– 2016. Infection and Drug Resistance, 2019, Volume 12, 3275-3281.	1.1	2
24	Geographical Variability Affects CCHFV Detection by RT–PCR: A Tool for In-Silico Evaluation of Molecular Assays. Viruses, 2019, 11, 953.	1.5	10
25	Pulmonary Involvement during the Ebola Virus Disease. Viruses, 2019, 11, 780.	1.5	6
26	Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. Lancet Infectious Diseases, The, 2019, 19, e444-e451.	4.6	14
27	<p>A case of persistent bacteraemia by <em>Ralstonia mannitolilytica</em> and <em>Ralstonia pickettii</em> in an intensive care unit</p> . Infection and Drug Resistance, 2019, Volume 12, 2391-2395.	1.1	27
28	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	1.2	46
29	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 1363-1367.	1.3	21
30	Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014–2016 Outbreak in West Africa. Viruses, 2019, 11, 373.	1.5	28
31	Epidemiological investigation of an Acinetobacter baumannii outbreak using core genome multilocus sequence typing. Journal of Global Antimicrobial Resistance, 2019, 17, 245-249.	0.9	20
32	Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. PLoS ONE, 2019, 14, e0212948.	1.1	22
33	Orthopoxvirus Seroprevalence in Cats and Veterinary Personnel in North-Eastern Italy in 2011. Viruses, 2019, 11, 101.	1.5	4
34	Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study. Journal of Infectious Diseases, 2019, 220, 195-202.	1.9	38
35	Viral Hemorrhagic Fevers Other than Ebola and Lassa. Infectious Disease Clinics of North America, 2019, 33, 977-1002.	1.9	32
36	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaÃīve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. HIV Medicine, 2019, 20, 99-109.	1.0	19

#	Article	IF	CITATIONS
37	Putting in Harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for Multidrug-Resistant Tuberculosis. , 2019, , .		3
38	Laboratory management of Crimean-Congo haemorrhagic fever virus infections: perspectives from two European networks. Eurosurveillance, 2019, 24, .	3.9	27
39	Occupational transmission of an Orthopoxvirus infection during an outbreak in a colony of <i>Macaca tonkeana</i> in Lazio Region, Italy, 2015. Zoonoses and Public Health, 2018, 65, 578-583.	0.9	7
40	Infections in liver and lung transplant recipients: a national prospective cohort. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 399-407.	1.3	37
41	Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. Clinical Infectious Diseases, 2018, 66, 36-44.	2.9	12
42	EBOLA Ag K-SeT rapid test: field evaluation in Sierra Leone. Clinical Microbiology and Infection, 2018, 24, 653-657.	2.8	10
43	Emerging infections—an increasingly important topic: review by the Emerging Infections Task Force. Clinical Microbiology and Infection, 2018, 24, 369-375.	2.8	44
44	Reply to Reisler et al. Clinical Infectious Diseases, 2018, 66, 1480-1481.	2.9	0
45	Emergence of colistin resistance in <i>Enterobacter aerogenes</i> from Croatia. Journal of Chemotherapy, 2018, 30, 120-123.	0.7	12
46	Evaluation of a rapid and sensitive RT-qPCR assay for the detection of Ebola Virus. Journal of Virological Methods, 2018, 252, 70-74.	1.0	21
47	Local transmission of chikungunya in Rome and the Lazio region, Italy. PLoS ONE, 2018, 13, e0208896.	1.1	33
48	The Surveillance of Chikungunya Virus in a Temperate Climate: Challenges and Possible Solutions from the Experience of Lazio Region, Italy. Viruses, 2018, 10, 501.	1.5	17
49	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	1.3	8
50	Molecular Characterization of Autochthonous Chikungunya Cluster in Latium Region, Italy. Emerging Infectious Diseases, 2018, 24, 178-180.	2.0	17
51	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine, 2018, 19, 475-484.	1.0	13
52	The European Virus Archive goes global: A growing resource for research. Antiviral Research, 2018, 158, 127-134.	1.9	30
53	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine, 2018, 16, 79.	2.3	24
54	Genetic Diversity of <b><i>Mycobacterium tuberculosis</i></b> Isolates in the Metropolitan Area of Rome. Chemotherapy, 2018, 63, 148-154.	0.8	1

#	Article	IF	CITATIONS
55	Status, quality and specific needs of Ebola virus diagnostic capacity and capability in laboratories of the two European preparedness laboratory networks EMERGE and EVD-LabNet. Eurosurveillance, 2018, 23, .	3.9	9
56	Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. The Lancet Global Health, 2017, 5, e80-e88.	2.9	100
57	Ebola virus infection induces autoimmunity against dsDNA and HSP60. Scientific Reports, 2017, 7, 42147.	1.6	14
58	Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature, 2017, 544, 309-315.	13.7	346
59	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA â‰ <b>g</b> OÂcp/mL. Infection, 2017, 45, 521-528.	2.3	10
60	Evaluation of the inactivation effect of Triton X-100 on Ebola virus infectivity. Journal of Clinical Virology, 2017, 86, 27-30.	1.6	27
61	Circulation of <i>bla</i> <sub>KPC-3</sub> -Carrying IncX3 Plasmids among Citrobacter freundii Isolates in an Italian Hospital. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	19
62	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clinical Microbiology and Infection, 2017, 23, 267.e1-267.e4.	2.8	11
63	Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent with Bacterial Translocation across the Gut. MSphere, 2017, 2, .	1.3	30
64	Human Zika infection induces a reduction of IFN- $\hat{1}^3$ producing CD4 T-cells and a parallel expansion of effector VÎ <sup>2</sup> T-cells. Scientific Reports, 2017, 7, 6313.	1.6	35
65	Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 417-422.	0.9	2
66	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 465-471.	0.9	4
67	Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays. Microbial Drug Resistance, 2017, 23, 507-515.	0.9	1
68	The contribution of the European high containment laboratories during the 2014–2015 Ebola Virus Disease emergency. Clinical Microbiology and Infection, 2017, 23, 58-60.	2.8	3
69	Exploring MALDI-TOF MS approach for a rapid identification ofMycobacterium aviumssp.paratuberculosisfield isolates. Journal of Applied Microbiology, 2017, 122, 568-577.	1.4	8
70	Full-Length Genome Sequence of a Chikungunya Virus Isolate from the 2017 Autochthonous Outbreak, Lazio Region, Italy. Genome Announcements, 2017, 5, .	0.8	10
71	Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report. BMC Infectious Diseases, 2017, 17, 597.	1.3	4
72	Fatal Outbreak in Tonkean Macaques Caused by Possibly Novel Orthopoxvirus, Italy, January 20151. Emerging Infectious Diseases, 2017, 23, 1941-1949.	2.0	27

#	Article	IF	CITATIONS
73	Measles Cases during Ebola Outbreak, West Africa, 2013–2106. Emerging Infectious Diseases, 2017, 23, 1035-1037.	2.0	21
74	Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Neglected Tropical Diseases, 2017, 11, e0005645.	1.3	46
75	Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. PLoS Pathogens, 2017, 13, e1006065.	2.1	14
76	Letter to the Editor: Surveillance of mcr-1 and mcr-2 genes in Carbapenem-resistant Klebsiella pneumoniae strains from an Italian Hospital. Eurosurveillance, 2017, 22, .	3.9	10
77	Molecular Typing of Mycobacterium tuberculosis Strains: A Fundamental Tool for Tuberculosis Control and Elimination. Gastroenterology Insights, 2016, 8, 6567.	0.7	19
78	Clinical, Virologic, and Epidemiologic Characteristics of Dengue Outbreak, Dar es Salaam, Tanzania, 2014. Emerging Infectious Diseases, 2016, 22, 895-899.	2.0	39
79	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Medicine, 2016, 13, e1001967.	3.9	382
80	Diagnosis of Zika virus infection in pregnant women travelling to or residing in endemic areas. Lancet Infectious Diseases, The, 2016, 16, 771-772.	4.6	4
81	Sampling Surfaces for Ebola Virus Persistence After Cleaning Procedures in High-Level Isolation Settings: The Experience With 2 Patients at the Lazzaro Spallanzani National Institute for Infectious Diseases. Infection Control and Hospital Epidemiology, 2016, 37, 723-725.	1.0	4
82	Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. Cell Death and Disease, 2016, 7, e2164-e2164.	2.7	51
83	Unique human immune signature of Ebola virus disease in Guinea. Nature, 2016, 533, 100-104.	13.7	170
84	Non-randomised Ebola trials—lessons for optimal outbreak research. Lancet Infectious Diseases, The, 2016, 16, 407-408.	4.6	5
85	Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015. Journal of Infectious Diseases, 2016, 214, S250-S257.	1.9	32
86	Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1247-1258.	1.3	75
87	Rapid outbreak sequencing of Ebola virus in Sierra Leone identifies transmission chains linked to sporadic cases. Virus Evolution, 2016, 2, vew016.	2.2	105
88	Enabling Rapid Response to the 2014–2016 Ebola Epidemic: The Experience and the Results of the National Institute for Infectious Diseases Lazzaro Spallanzani. Advances in Experimental Medicine and Biology, 2016, 972, 103-122.	0.8	2
89	Three cases of Zika virus imported in Italy: need for a clinical awareness and evidence-based knowledge. BMC Infectious Diseases, 2016, 16, 669.	1.3	7
90	Temporary neurocognitive impairment with Ebola virus. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1386-1387.	0.9	11

#	Article	IF	CITATIONS
91	Prioritization of High Consequence Viruses to Improve European Laboratory Preparedness for Cross-Border Health Threats. Advances in Experimental Medicine and Biology, 2016, 972, 123-129.	0.8	2
92	Steroid use and clinical sequelae in two survivors of EVD. Lancet Infectious Diseases, The, 2016, 16, 638.	4.6	2
93	Real-time, portable genome sequencing for Ebola surveillance. Nature, 2016, 530, 228-232.	13.7	1,179
94	Dilemmas in Managing Pregnant Women With Ebola: 2 Case Reports: Table 1 Clinical Infectious Diseases, 2016, 62, 903-905.	2.9	56
95	INMI/Emergency NGO Italian Laboratory Established In Sierra Leone during Ebola Virus Disease Outbreak in West Africa. Clinical Microbiology and Infectious Diseases, 2016, 1, .	0.1	5
96	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	1.1	0
97	Zika virus and microcephaly: is the correlation, causal or coincidental?. New Microbiologica, 2016, 39, 83-85.	0.1	1
98	Isolation of KPC 3-producing Enterobacter aerogenes in a patient colonized by MDR Klebsiella pneumoniae. New Microbiologica, 2016, 39, 310-313.	0.1	1
99	Short-term economic impact of the Zika virus outbreak. New Microbiologica, 2016, 39, 287-289.	0.1	30
100	Criteria for discharge of patients with Ebola virus diseases in high-income countries. The Lancet Global Health, 2015, 3, e739-e740.	2.9	11
101	Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infectious Diseases, 2015, 15, 432.	1.3	36
102	Molecular Signature of the Ebola Virus Associated with the Fishermen Community Outbreak in Aberdeen, Sierra Leone, in February 2015. Genome Announcements, 2015, 3, .	0.8	3
103	The chronology of the international response to Ebola in Western Africa: lights and shadows in a frame of conflicting position and figures. Gastroenterology Insights, 2015, 7, 5957.	0.7	8
104	Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?. Lancet Infectious Diseases, The, 2015, 15, 738-745.	4.6	42
105	Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death and Differentiation, 2015, 22, 1250-1259.	5.0	127
106	Molecular Characterization of the First Ebola Virus Isolated in Italy, from a Health Care Worker Repatriated from Sierra Leone. Genome Announcements, 2015, 3, .	0.8	10
107	Ebola: missed opportunities for Europe–Africa research. Lancet Infectious Diseases, The, 2015, 15, 1254-1255.	4.6	13
108	Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1967-73.	1.4	14

#	Article	IF	CITATIONS
109	Identification of Highly Pathogenic Microorganisms by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry: Results of an Interlaboratory Ring Trial. Journal of Clinical Microbiology, 2015, 53, 2632-2640.	1.8	71
110	Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa. Nature, 2015, 524, 97-101.	13.7	272
111	The added value of long-lasting preparedness for the management of a patient with Ebola. European Journal of Internal Medicine, 2015, 26, 451-452.	1.0	7
112	Hospital preparedness for knowledge-based response to Ebola and other emerging infectious diseases: A continuous challenge. European Journal of Internal Medicine, 2015, 26, 454-455.	1.0	4
113	Field Evaluation of Capillary Blood Samples as a Collection Specimen for the Rapid Diagnosis of Ebola Virus Infection During an Outbreak Emergency. Clinical Infectious Diseases, 2015, 61, 669-675.	2.9	28
114	Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014. Journal of Clinical Virology, 2015, 62, 124-134.	1.6	27
115	Blood kinetics of Ebola virus in survivors and nonsurvivors. Journal of Clinical Investigation, 2015, 125, 4692-4698.	3.9	82
116	Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. Journal of Clinical Investigation, 2015, 125, 4421-4428.	3.9	102
117	Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro. PLoS ONE, 2015, 10, e0116816.	1.1	15
118	Mobile diagnostics in outbreak response, not only for Ebola: a blueprint for a modular and robust field laboratory. Eurosurveillance, 2015, 20, .	3.9	45
119	Benefits of a European Project on Diagnostics of Highly Pathogenic Agents and Assessment of Potential ââ,¬Å"Dual Useââ,¬Â•lssues. Frontiers in Public Health, 2014, 2, 199.	1.3	7
120	lgG Against Dengue Virus in Healthy Blood Donors, Zanzibar, Tanzania. Emerging Infectious Diseases, 2014, 20, 465-8.	2.0	33
121	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	1.3	6
122	Evidence for a decrease in transmission of Ebola virusLofa County, Liberia, June 8-November 1, 2014. Morbidity and Mortality Weekly Report, 2014, 63, 1067-71.	9.0	20
123	<i>In Vitro</i> Activity of Doripenem in Combination with Various Antimicrobials Against Multidrug-Resistant <i>Acinetobacter baumannii</i> : Possible Options for the Treatment of Complicated Infection. Microbial Drug Resistance, 2013, 19, 407-414.	0.9	38
124	High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clinical Microbiology and Infection, 2013, 19, E23-E30.	2.8	256
125	Heterogeneity of West Nile virus genotype 1a in Italy, 2011. Journal of General Virology, 2013, 94, 314-317.	1.3	5
126	Cystic Echinococcosis in a Single Tertiary Care Center in Rome, Italy. BioMed Research International, 2013, 2013, 1-9.	0.9	19

#	Article	IF	CITATIONS
127	Biosafety Level-4 Laboratories in Europe: Opportunities for Public Health, Diagnostics, and Research. PLoS Pathogens, 2013, 9, e1003105.	2.1	19
128	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1–. European Respiratory Journal, 2012, 40, 497-500.	3.1	20
129	Seroprevalence of dengue infection: a cross-sectional survey in mainland Tanzania and on Pemba Island, Zanzibar. International Journal of Infectious Diseases, 2012, 16, e44-e46.	1.5	49
130	Daptomycin efficacy in the central nervous system of a patient with disseminated methicillin-resistant Staphylococcus aureus infection: a case report. Journal of Medical Case Reports, 2012, 6, 264.	0.4	7
131	Results of anti-Toxoplasma gondii IgG, IgM, IgA and IgG Avidity testing in pregnant women in Rome, Italy. Microbiologia Medica, 2012, 27, .	0.3	Ο
132	Role of serum free light chains in predicting HIVâ€associated nonâ€Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. American Journal of Hematology, 2012, 87, 749-753.	2.0	24
133	Viral hemorrhagic fevers: advancing the level of treatment. BMC Medicine, 2012, 10, 31.	2.3	39
134	Cowpox Virus in Llama, Italy. Emerging Infectious Diseases, 2011, 17, 1513-5.	2.0	27
135	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. Aids, 2011, 25, 1385-1394.	1.0	155
136	Phylogenetic Analysis of West Nile Virus Isolates, Italy, 2008–2009. Emerging Infectious Diseases, 2011, 17, 903-906.	2.0	34
137	Chikungunya virus isolates with/without A226V mutation show different sensitivity to IFN-a, but similar replication kinetics in non human primate cells. New Microbiologica, 2011, 34, 87-91.	0.1	13
138	Design and clinical application of a molecular method for detection and typing of the influenza A/H1N1pdm virus. Journal of Virological Methods, 2010, 163, 486-488.	1.0	11
139	The prevalence of antibodies to human herpesvirus 8 and hepatitis B virus in patients in two hospitals in Tanzania. Journal of Medical Virology, 2010, 82, 1569-1575.	2.5	14
140	Alkhurma Hemorrhagic Fever in Travelers Returning from Egypt, 2010. Emerging Infectious Diseases, 2010, 16, 1979-1982.	2.0	63
141	Absence of Neuroinvasive Disease in a Liver Transplant Recipient Who Acquired West Nile Virus (WNV) Infection from the Organ Donor and Who Received WNV Antibodies Prophylactically. Clinical Infectious Diseases, 2010, 51, e34-e37.	2.9	47
142	Frequency of Detection of Upper Respiratory Tract Viruses in Patients Tested for Pandemic H1N1/09 Viral Infection. Journal of Clinical Microbiology, 2010, 48, 3383-3385.	1.8	30
143	Alkhurma Hemorrhagic Fever in Travelers Returning from Egypt, 2010. Emerging Infectious Diseases, 2010, 16, 1979-82.	2.0	32
144	Cat-to-Human Orthopoxvirus Transmission, Northeastern Italy. Emerging Infectious Diseases, 2009, 15, 499-500.	2.0	24

#	Article	IF	CITATIONS
145	Crimean-Congo Hemorrhagic Fever, Southwestern Bulgaria. Emerging Infectious Diseases, 2009, 15, 983-985.	2.0	44
146	European Perspective of 2-Person Rule for Biosafety Level 4 Laboratories. Emerging Infectious Diseases, 2009, 15, 1858a-1860.	2.0	3
147	Transgenic chloroplasts are efficient sites for highâ€yield production of the vaccinia virus envelope protein A27L in plant cellsâ€. Plant Biotechnology Journal, 2009, 7, 577-591.	4.1	35
148	Training health care workers to face highly infectious diseases. Clinical Microbiology and Infection, 2009, 15, 740-742.	2.8	10
149	Facing the threat of highly infectious diseases in Europe: the need for a networking approach. Clinical Microbiology and Infection, 2009, 15, 706-710.	2.8	4
150	The European network of Biosafety-Level-4 laboratories: enhancing European preparedness for new health threats. Clinical Microbiology and Infection, 2009, 15, 720-726.	2.8	22
151	A critical reappraisal of the A226V mutation in chikungunya outbreaks: Possible role in increased pathogenesis?. Cytokine, 2009, 48, 78-79.	1.4	Ο
152	Accuracy of Malaria Diagnosis by Microscopy, Rapid Diagnostic Test, and PCR Methods and Evidence of Antimalarial Overprescription in Non-Severe Febrile Patients in Two Tanzanian Hospitals. American Journal of Tropical Medicine and Hygiene, 2009, 80, 712-717.	0.6	60
153	Accuracy of malaria diagnosis by microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial overprescription in non-severe febrile patients in two Tanzanian hospitals. American Journal of Tropical Medicine and Hygiene, 2009, 80, 712-7.	0.6	38
154	Ebolavirus and Marburgvirus: Insight the Filoviridae family. Molecular Aspects of Medicine, 2008, 29, 151-185.	2.7	84
155	Presence of the A226V Mutation in Autochthonous and Imported Italian Chikungunya Virus Strains. Clinical Infectious Diseases, 2008, 47, 428-429.	2.9	42
156	West Nile virus in Italy: a further threat to blood safety, a further challenge to the blood system. Blood Transfusion, 2008, 6, 235-7.	0.3	32
157	Diagnostic Reverseâ€Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories. Journal of Infectious Diseases, 2007, 196, S199-S204.	1.9	65
158	A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader?. Journal of Travel Medicine, 2007, 14, 346-348.	1.4	27
159	Rapid Detection and Quantification of Chikungunya Virus by a One-Step Reverse Transcription–Polymerase Chain Reaction Real-Time Assay. American Journal of Tropical Medicine and Hygiene, 2007, 77, 521-524.	0.6	44
160	Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay. American Journal of Tropical Medicine and Hygiene, 2007, 77, 521-4.	0.6	13
161	Bcl-2 inhibits the caspase-dependent apoptosis induced by SARS-CoV without affecting virus replication kinetics. Archives of Virology, 2006, 151, 369-377.	0.9	40
162	Role of Intravenous Immunoglobulin Administration in Japanese Encephalitis. Clinical Infectious Diseases, 2006, 43, 1620-1621.	2.9	28

#	Article	IF	CITATIONS
163	Indomethacin has a potent antiviral activity against SARS coronavirus. Antiviral Therapy, 2006, 11, 1021-30.	0.6	92
164	Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus. Antiviral Therapy, 2006, 11, 1021-1030.	0.6	163
165	Sepharose-bound, highly sulfated glycosaminoglycans can capture HIV-1 from culture medium. Carbohydrate Research, 2005, 340, 759-764.	1.1	0
166	The Initial Hospital Response to an Epidemic. Archives of Medical Research, 2005, 36, 706-712.	1.5	12
167	Rapid, differential diagnosis of orthopox- and herpesviruses based upon real-time PCR product melting temperature and restriction enzyme analysis of amplicons. Journal of Virological Methods, 2005, 129, 97-100.	1.0	18
168	A molecular beacon, bead-based assay for the detection of nucleic acids by flow cytometry. Nucleic Acids Research, 2005, 33, e13-e13.	6.5	76
169	Severe Acute Respiratory Syndrome–Related Coronavirus Is Inhibited by Interferonâ€Î±. Journal of Infectious Diseases, 2004, 189, 1164-1167.	1.9	206
170	Acute fatal necrotizing hemorrhagic encephalitis caused by Epstein-Barr virus in a young adult immunocompetent man. Journal of NeuroVirology, 2004, 10, 414-417.	1.0	35
171	Susceptibility to highly sulphated glycosaminoglycans of human immunodeficiency virus type 1 replication in peripheral blood lymphocytes and monocyte-derived macrophages cell cultures. Antiviral Research, 2003, 58, 139-147.	1.9	12
172	Soluble proteolytic enzyme release by naive and HIV-infected cultured T-cells. International Immunopharmacology, 2003, 3, 615-626.	1.7	0
173	Comparative Analysis of Total and Integrated HIV-1 DNA in Peripheral CD4 Lymphocytes and Monocytes After Long Treatment with HAART. Journal of Infection, 2001, 43, 239-245.	1.7	23
174	"Tissue―Transglutaminase Expression in HIVâ€Infected Cells. Annals of the New York Academy of Sciences, 2001, 946, 108-120.	1.8	18
175	"Tissue" transglutaminase expression in HIV-infected cells: an enzyme with an antiviral effect?. Annals of the New York Academy of Sciences, 2001, 946, 108-20.	1.8	10
176	Fractions of Chemically Oversulphated Galactosaminoglycan Sulphates Inhibit Three Enveloped Viruses: Human Immunodeficiency Virus Type 1, Herpes Simplex Virus Type 1 and Human Cytomegalovirus. Antiviral Chemistry and Chemotherapy, 1999, 10, 33-38.	0.3	14
177	Failure of HIV-1 to Infect Human Oocytes Directly. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 355.	0.9	22
178	The debate on the presence of HIV-1 in human gametes. Journal of Reproductive Immunology, 1998, 41, 41-67.	0.8	65
179	Grossly Defective <i>nef</i> Gene Sequences in a Human Immunodeficiency Virus Type 1-Seropositive Long-Term Nonprogressor. Journal of Virology, 1998, 72, 3646-3657.	1.5	171
180	Correlation between Epstein Barr virus antibodies, serum IgE and atopic disease. Pediatric Allergy and Immunology, 1997, 8, 91-96.	1.1	28

#	Article	IF	CITATIONS
181	In vitro activation of HIV RNA expression in peripheral blood lymphocytes as a marker to predict the stability of non-progressive status in long-term survivors. Aids, 1996, 10, 17-22.	1.0	11
182	Peripheral lymphocytes of clinically non-progressor patients harbor inactive and uninducible HIV proviruses. Journal of Medical Virology, 1995, 46, 116-121.	2.5	10
183	HIV-particles in spermatozoa of patients with AIDS and their transfer into the oocyte. Journal of Cell Biology, 1994, 127, 903-914.	2.3	154
184	Herion addicts infected by HBV and HIV have a low prevalence of HBV DNA in peripheral blood mononuclear cells. Journal of Medical Virology, 1993, 41, 114-119.	2.5	8
185	Identification of a CD21 receptor-deficient, non-Ig-secreting peripheral B lymphocyte subset in HIV-seropositive drug abusers. Clinical Immunology and Immunopathology, 1992, 62, 139-147.	2.1	12